Abstract:Introduction: Copper-64 (64Cu, t1/2 = 12.7 h) is a positron emitter well suited for theranostic applications with beta-emitting 67Cu for targeted molecular imaging and radionuclide therapy. The present work aims to evaluate the radionuclidic purity and radiochemistry of 64Cu produced via the 68Zn(p,nα)64Cu nuclear reaction. Macrocyclic chelators DOTA, NOTA, TETA, and prostate-specific membrane antigen ligand PSMA I&T were radiolabeled with purified 64Cu and tested for in vitro stability. [64Cu]Cu-PSMA I&T was used to demonstrate in vivo PET imaging using 64Cu synthesized via the 68Zn(p,nα)64Cu production route and its suitability as a theranostic imaging partner alongside 67Cu therapy. Methods: 64Cu was produced on a 24 MeV TR-24 cyclotron at a beam energy of 23.5 MeV and currents up to 70 μA using 200 mg 68Zn encapsulated within an aluminum‑indium-graphite sealed solid target assembly. 64Cu semi-automated purification was performed using a NEPTIS Mosaic-LC synthesis unit employing CU, TBP, and TK201 (TrisKem) resins. Radionuclidic purity was measured by HPGe gamma spectroscopy, while ICP-OES assessed elemental purity. Radiolabeling was performed with NOTA at room temperature and DOTA, TETA, and PSMA I&T at 95 °C. 64Cu incorporation was studied by radio-TLC. 64Cu in vitro stability of [64Cu]Cu-NOTA, [64Cu]Cu-DOTA, [64Cu]Cu-TETA, and [64Cu]Cu-PSMA I&T was assessed at 37 °C from 0 to 72 h in human blood serum. Preclinical PET imaging was performed at 1, 24, and 48 h post-injection with [64Cu]Cu-PSMA I&T in LNCaP tumor-bearing mice and compared with [68Ga]Ga-PSMA I&T. Results: Maximum purified activity of 4.9 GBq [64Cu]CuCl2 was obtained in 5 mL of pH 2-3 solution, with 2.9 GBq 64Cu concentrated in 0.5 mL. HPGe gamma spectroscopy of purified 64Cu detected <0.3 % co-produced 67Cu at EOB with no other radionuclidic impurities. ICP-OES elemental analysis determined <1 ppm Al, Zn, In, Fe, and Cu in the [64Cu]CuCl2 product. NOTA, DOTA, TETA, and PSMA I&T were radiolabeled with 64Cu, resulting in maximum molar activities of 164 ± 6 GBq/μmol, 155 ± 31 GBq/μmol, 266 ± 34 GBq/μmol, and 117 ± 2 GBq/μmol, respectively. PET imaging in PSMA-expressing LNCaP xenografts resulted in high tumor uptake (SUVmean = 1.65 ± 0.1) using [64Cu]Cu-PSMA I&T, while [68Ga]Ga-PSMA I&T yielded an SUVmean of 0.76 ± 0.14 after 60 min post-injection. Conclusions: 64Cu was purified in a small volume amenable for radiolabeling, with yields suitable for preclinical and clinical application. The 64Cu production and purification process and the favourable PET imaging properties confirm the 68Zn(p,nα)64Cu nuclear reaction as a viable 64Cu production route for facilities with access to a higher energy proton cyclotron, compared to using expensive 64Ni target material and the 64Ni(p,n)64Cu nuclear reaction. Advances in knowledge and implications for patient care: Our 64Cu production technique provides an alternative production route with the potential to improve 64Cu availability for preclinical and clinical studies alongside 67Cu therapy.

A novel approach to medical radioisotope production using inverse kinematics: a successful production test of the theranostic radionuclide 67Cu

New developments for theranostic radioisotope production with solid targets at the Bern medical cyclotron

Production of Medical Radioisotopes with High Specific Activity in Photonuclear Reactions with $γ$ Beams of High Intensity and Large Brilliance

New developments in the production of theranostic pairs of radionuclides

Nuclear data for light charged particle induced production of emerging medical radionuclides

Radioisotopes production using lasers: from basic science to applications

Radioisotope production using lasers: From basic science to applications

64Cu production via the 68Zn(p,nα)64Cu nuclear reaction: An untapped, cost-effective and high energy production route

Production of copper-64 and gallium-68 with a medical cyclotron using liquid targets

Production, Quality Control and Micro PET Analysis of Novel Solid-Target Based Radionuclide 64 Cu

Establishing Reliable Cu-64 Production Process: From Target Plating To Molecular Specific Tumor Micro-Pet Imaging

ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine

GEANT4 simulation of cyclotron radioisotope production in a solid target

Production, purification and formulation of nanoradiopharmaceutical with 211At: An emerging candidate for targeted alpha therapy

From cyclotrons to chromatography and beyond: a guide to the production and purification of theranostic radiometals

Novel method for fast neutron irradiation of materials via positron emission tomography isotope producing cyclotron

Production of Y-86 and other radiometals for research purposes using a solution target system

Generation of Medical Isotopes 47-Sc, 67-Cu Through Laser-Induced (γ, P) Reaction

Development of Target Holder for the First Experiment on an Alternative Route for 64Cu Radioisotope Production by Secondary Neutron Irradiation of a 64ZnO Target

Optimized simulations of 50Ti(p,α) and 49Ti(d,α) reactions for hospital-cyclotron production of 47Sc

Hybridised production of technetium-99m and technetium-101 with fluorine-18 on a low-energy biomedical cyclotron